Amylyx Pharmaceuticals Files DEFA14A Proxy Materials
Ticker: AMLX · Form: DEFA14A · Filed: Apr 23, 2026 · CIK: 0001658551
Sentiment: neutral
Topics: proxy, filing
Related Tickers: AMYX
TL;DR
AMYX filed proxy docs, nothing new for traders.
AI Summary
Amylyx Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on April 23, 2026. This filing is related to proxy materials and does not contain specific financial details or proposals. The company's principal executive offices are located at 55 Cambridge Parkway, Suite 6W, Cambridge, MA 02142.
Why It Matters
This filing indicates routine corporate actions and shareholder communication, which is standard for publicly traded companies but doesn't offer new investment insights.
Risk Assessment
Risk Level: low — This filing is a routine DEFA14A, which typically contains additional proxy soliciting materials and does not present new financial or strategic information.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Filer
- 0001658551 (company) — CIK Number
- 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142 (company) — Mailing and Business Address
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, which signifies Additional definitive proxy soliciting materials and Rule 14(a)(12) material.
When was this filing accepted by the SEC?
The filing was accepted on 2026-04-23 at 07:02:00.
What is the CIK number for Amylyx Pharmaceuticals, Inc.?
The CIK number for Amylyx Pharmaceuticals, Inc. is 0001658551.
What is the business address of Amylyx Pharmaceuticals, Inc.?
The business address is 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142.
What is the SIC code for Amylyx Pharmaceuticals, Inc.?
The SIC code is 2834, categorized under Pharmaceutical Preparations (CF Office: 03 Life Sciences).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 23, 2026 regarding Amylyx Pharmaceuticals, Inc. (AMLX).